TBI

TrueBlue is a classic beaten-down staffing cyclical: revenue has fallen from a $2.25B peak in FY2022 to $1.62B in FY2025, and the company has now booked three straight annual net losses (-$14.2M, -$126M, -$48.0M). The one encouraging thread is that the bleeding is slowing — the FY2025 net loss of -$48.0M is a 61.9% improvement year-over-year and revenue actually ticked up +3.1%. On valuation alone the stock looks abandoned: at $6.75 the $203M market cap sits roughly 26% below the $275M of stockholders' equity, and P/S is a rounding error at 0.1x. That is the entire bull case — you are buying a leveraged bet on a staffing-cycle recovery for less than tangible book.

The problem is the cash. Operating cash flow swung to -$58.0M (down 240% YoY) and capex adds another $15.7M, implying roughly -$74M of free cash burn against just $24.5M of cash on hand. Management funded the gap partly by lifting long-term debt 766% to $65.8M off a tiny base. Gross profit fell 9.5% even as revenue rose, so gross margin compressed to 22.8% — the mix and pricing are working against them, not just volume. For a company whose MD&A leans on workers'-compensation reserve releases ('positively impacted primarily by the success of our accident prevention programs') to flatter cost of services, that tailwind is finite and, by management's own admission, will 'diminish' if accident rates stop falling.